Inotek shares soar as glaucoma drug heads to PhIII

Shares of Inotek Pharmaceuticals ($ITEK) soared 65% Thursday morning, after the Lexington, MA-based biotech said that it had completed an end-of-Phase II meeting with the FDA and set up a Phase III strategy for its glaucoma drug trabodenoson. David Southwell, CEO of the little biotech, said that "we expect to commence our first Phase III trial in 4Q and look forward to data in 2016." Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.